» Articles » PMID: 32447370

Impact of Meningococcal B (4CMenB) Vaccine on Pharyngeal Neisseria Meningitidis Carriage Density and Persistence in Adolescents

Overview
Journal Clin Infect Dis
Date 2020 May 25
PMID 32447370
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Higher density of Neisseria meningitidis carriage may be associated with transmission of the meningococcus. Our aim was to establish the impact of meningococcal B (4CMenB) vaccine on N. meningitidis carriage density.

Methods: We compared 4CMenB vaccine to control among 913 South Australian students aged approximately 15-18 years in a cluster randomized trial who had N. meningitidis carriage at 12 months. Oropharyngeal swabs were collected at baseline and 12 months later to detect N. meningitidis carriage. Colony-forming units per milliliter (CFU/mL) were estimated by generating a standard curve that plotted quantitative polymerase chain reaction cycle threshold values against log-normalized CFU.

Results: Among the 913 students with N. meningitidis carriage at 12 months, there was no difference in mean carriage density between the vaccinated (n = 434; 3.80 log CFU/mL [standard deviation {SD}, 1.29]) and control group (n = 479; 3.73 log CFU/mL [SD, 1.30]; P = .51). Higher N. meningitidis carriage density at baseline was associated with an increase in the odds of persistent carriage at 12 months (n = 504; odds ratio [OR] per 1.0 log CFU/mL increase in density, 1.36 [95% confidence interval {CI}, 1.17-1.58]; P < .001). Students with baseline carriage who were vaccinated had decreased persistent N. meningitidis carriage at 12 months compared to unvaccinated students (81/260 [31%] vs 105/244 [43%]; OR, 0.60 [95% CI, .40-.90]; P = .01).

Conclusions: 4CMenB vaccine did not reduce carriage density of N. meningitidis 12 months postvaccination, despite increased carriage clearance. Higher carriage density is likely to enable transmission through prolonged periods of population exposure.

Clinical Trials Registration: NCT03089086.

Citing Articles

The genomic epidemiology of carriage from a randomised controlled trial of 4CMenB vaccination in an asymptomatic adolescent population.

Leong L, Coldbeck-Shackley R, McMillan M, Bratcher H, Turra M, Lawrence A Lancet Reg Health West Pac. 2024; 43:100966.

PMID: 38169944 PMC: 10758868. DOI: 10.1016/j.lanwpc.2023.100966.


Meningococcal carriage in children and young adults: a cross-sectional and longitudinal study, Iceland, 2019 to 2021.

Kristinsdottir I, Visser L, Miellet W, Mariman R, Pluister G, Haraldsson G Euro Surveill. 2023; 28(39).

PMID: 37768562 PMC: 10540516. DOI: 10.2807/1560-7917.ES.2023.28.39.2300215.


Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in Adolescents.

McMillan M, Bednarz J, Leong L, Lawrence A, Marshall H Pediatr Infect Dis J. 2022; 41(11):e468-e474.

PMID: 35895880 PMC: 9555590. DOI: 10.1097/INF.0000000000003660.


Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®.

Kensinger R, Arunachalam A Glycoconj J. 2022; 39(3):381-392.

PMID: 35441968 PMC: 9019543. DOI: 10.1007/s10719-022-10050-2.


A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex With Men.

Hui B, Padeniya T, Rebuli N, Gray R, Wood J, Donovan B J Infect Dis. 2021; 225(6):983-993.

PMID: 34894134 PMC: 8922007. DOI: 10.1093/infdis/jiab581.